Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx UK II
AAV RPE65 is an adeno-associated viral vector gene therapy that delivers the RPE65 gene. It is being studied in Leber congenital amaurosis, an inherited retinal disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02781480 | Phase 1/2 | Leber Congenital Amaurosis | Completed | MGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Leber Congenital Amaurosis
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.
See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGTX catalysts and pipeline →